Research and development of antibiotics: insights from patents and citation network

References

• Power E. Impact of antibiotic restrictions: the pharmaceutical perspective. Clin Microbiol Infect. 2006;12(Suppl 5):25–34.
   PubMed Web of Science ®Google Scholar
• Oldfield E, Feng X. Resistance-resistant antibiotics. Trends Pharmacol Sci. 2014;35(12):664–674.
   PubMed Web of Science ®Google Scholar
• D’Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. Nature. 2011;477(7365):457–461.
   PubMed Web of Science ®Google Scholar
• Wright GD. The antibiotic resistome: the nexus of chemical and genetic diversity. Nature Rev Microbiol. 2007;5(3):175–186.
   PubMed Web of Science ®Google Scholar
• Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–1098.
   PubMed Web of Science ®Google Scholar
• Oliphant CM, Eroschenko K. Antibiotic resistance, part 1: Gram-negative pathogens. J Nurse Prac. 2015;11(1):70–78.
   Google Scholar
• Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care associated infections and deaths in U.S. hospitals, 2002. Public Health Rep. 2007;122(2):160–166.
   PubMed Web of Science ®Google Scholar
• Rao CVS, Waelheyns ED, Economou A, et al. Antibiotic targeting of the bacterial secretory pathway. Biochim Biophys Acta. 2014;1843(8):1762–1783.
   PubMed Web of Science ®Google Scholar
• The Lancet Infectious Diseases. Antibiotic resistance: long-term solutions require action now. Lancet Infect Dis. 2013;13(12):995.
   PubMed Web of Science ®Google Scholar
• So AD, Gupta N, Brahmachari SK, et al. Towards new business models for R&D for novel antibiotics. Drug Resist Update. 2011;14(2):88–94.
   PubMed Web of Science ®Google Scholar
• Coates ARM, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br J Pharmacol. 2011;163(1):184–194.
   PubMed Web of Science ®Google Scholar
• Herrmann M, Nkuiya B, Dussault A. Innovation and antibiotic use within antibiotic classes: market incentives and economic instruments. Resour Energ Econ. 2013;35(4):582–598.
   Web of Science ®Google Scholar
• Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn? Int J Antimicrob Ag. 2009;34(1):15.
   PubMed Web of Science ®Google Scholar
• Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-time to react is now. Drug Resist Updates. 2011;14(2):118–124.
   PubMed Web of Science ®Google Scholar
• Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013;4(2):185–191.
   PubMed Web of Science ®Google Scholar
• Jabes D. The antibiotic R&D pipeline: an update. Curr Opin Microbiol. 2011;14(5):564–569.
   PubMed Web of Science ®Google Scholar
• Pucci MJ, Bush K. Investigational antimicrobial agents of 2013. Clin Microbiol Rev. 2013;26(4):792–821.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U. Resistance drives antibacterial drug development. Curr Opin Pharmacol. 2011;11(5):433–438.
   PubMed Web of Science ®Google Scholar
• Donadio S, Maffioli S, Monciardini P, et al. Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot. 2010;63(8):423–430.
   PubMed Web of Science ®Google Scholar
• Devasahayam G, Scheld WM, Hoffman PS. Newer antibacterial drugs for a new century. Expert Opin Inv Drug. 2010;19(2):215–234.
   PubMed Web of Science ®Google Scholar
• Page MGP, Bush K. Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? Curr Opin Pharmacol. 2014;18:91–97.
   PubMed Web of Science ®Google Scholar
• Xie H, Zhang H, Zhang S, et al. Analysis of antibiotic patents issued in China from 1992 to 2011. Expert Opin Ther Pat. 2012;22(10):1205–1232.
   PubMed Web of Science ®Google Scholar
• Bonfiglio G, Furneri PM. Patents on streptogramin antibiotics. Expert Opin Ther Pat. 2003;13(5):651–659.
   Web of Science ®Google Scholar
• Verma AK, Bhatia B, Nelson ML. Antibiotic and non-antibiotic tetracycline patents: 2002–2007. Expert Opin Ther Pat. 2008;18(1):69–82.
   Web of Science ®Google Scholar
• Li X, Chen H, Huang Z, et al. Patent citation network in nanotechnology (1976–2004). J Nanopart Res. 2007;9(3):337–352.
   Web of Science ®Google Scholar
• Xu J, Kong X, Qiu L, et al. Research and development of anti-Alzheimer’s drugs: ananalysis based on technology flows measured by patent citations. Expert Opin Ther Pat. 2014;24(7):791–800.
   PubMed Web of Science ®Google Scholar
• Stolpe M. Determinants of knowledge diffusion as evidenced in patent data: the case of liquid crystal display technology. Res Policy. 2002;31(7):1181–1198.
   Web of Science ®Google Scholar
• Érdi P, Makovi K, Somogyvári Z, et al. Prediction of emerging technologies based on analysis of the US patent citation network. Scientometrics. 2013;95(1):225–242.
   Web of Science ®Google Scholar
• Roberts M, Wall IB, Bingham I, et al. The global intellectual property landscape of induced pluripotent stem cell technologies. Nat Biotechnol. 2014;32(8):742–748.
   PubMed Web of Science ®Google Scholar
• Dara A, Sangamwar AT. Clearing the Fog of Anticancer Patents from 1993–2013: Through an In-Depth Technology Landscape & Target Analysis from Pioneer Research Institutes and Universities Worldwide. PLoS One. 2014;9(8):e103847.
   PubMed Web of Science ®Google Scholar
• Narin F. Patent bibliometrics. Scientometrics. 1994;30(1):147–155.
   Web of Science ®Google Scholar
• Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Med. 2006;119(6Suppl 1):SS3–10.
   PubMed Web of Science ®Google Scholar
• Sorenson O, Rivkin JW, Fleming L. Complexity, networks and knowledge flow. Res Policy. 2006;35(7):994–1017.
   Web of Science ®Google Scholar
• Wartburg I, Teichert T, Rost K. Inventive progress measured by multi-stage patent citation analysis. Res Policy. 2005;34(10):1591–1607.
   Web of Science ®Google Scholar
• Karki MMS, Krishnan KS. Patent citation analysis: a policy analysis tool. World Pat Inf. 1991;19(4):269–272.
   Google Scholar
• Blondel VD, Guillaume J, Lambiotte R, et al. Fast unfolding of communities in large networks. J Stat Mech-Theory E. 2008;10:P10008.
   Web of Science ®Google Scholar
• Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24(1):71–109.
   PubMed Web of Science ®Google Scholar
• Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014;28(6):25–64.
   Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, No drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
   PubMed Web of Science ®Google Scholar
• Chang S, Lai K, Chang S. Exploring technology diffusion and class cation of business methods: using the patent citation network. Technol Forecast Soc Change. 2009;76(1):107–117.
   Web of Science ®Google Scholar
• Messinis G. Triadic citations, country biases and patent value: the case of pharmaceuticals. Scientometrics. 2011;89(3):813–833.
   Web of Science ®Google Scholar
• Murima P, McKinney JD, Pethe K. Targeting bacterial central metabolism for drug development. Chem Biol. 2014;21(11):1423–1432.
   PubMed Web of Science ®Google Scholar
• Ochiai M, Morimoto A, Matsushita Y 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido] cephalosporins. US 4278671. 1981.
   Google Scholar
• Schwab W, Durckheimer W, Kirrstetter R, et al. Process for the preparation of cephem compounds. US 4667028. 1987.
   Google Scholar
• Agouridas C, Chantot J, Denis A, et al. Erythromycin compounds. US 5635485. 1997.
   Google Scholar
• Lattrell R, Wieduwilt M, Durckheimer W, et al. Cephalosporin derivatives. US 5071979. 1991.
   Google Scholar
• Fatheree PR, Linsell MS, Long DD, et al. Cross-linked glycopeptide-cephalosporin antibiotics. US 6974797. 2005.
   Google Scholar
• Long DD. Cross-linked glycopeptide-cephalosporin antibiotics. US 8557978. 2013.
   Google Scholar
• Fukuda Y, Takadoi M, Asahina Y, et al. Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position. US 8222407. 2012.
   Google Scholar
• Long DD. Cross-linked glycopeptide-cephalosporin antibiotics. US 8044195. 2011.
   Google Scholar
• Okuhara M, Tanaka H, Goto T, et al. Method for inhibiting interleukin-2 production using tricyclo compounds. US 6482845. 2002.
   Google Scholar
• Scherer FM. The political economy of patent policy reform in the United States. J Telecomm High Tech L. 2009;7(2):167–216.
   Google Scholar
• Outterson K, Samora JB, Keller-Cuda K. Will longer antimicrobial patents improve global public health? Lancet Infect Dis. 2007;7(8):559–566.
   PubMed Web of Science ®Google Scholar
• Mossialos E, Morel CM, Edwards S, et al. Policies and Incentives for Promoting Innovation in Antibiotic Research. European Observatory on Health Systems and Policies. 2010.
   Google Scholar
• Projan SJ. Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003;6(5):427–430.
   PubMed Web of Science ®Google Scholar
• Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J Antibiot. 2015. doi:10.1038/ja.2015.98. published online 14 October 2015.
   PubMed Web of Science ®Google Scholar
• Nathan C, Goldber FM. Outlook: the profit problem in antibiotic R&D. Nat Rev Drug Discov. 2005;4(11):887–891.
   PubMed Web of Science ®Google Scholar
• Bettiol E, Harbarth S. Development of new antibiotics: taking off finally? Swiss Med Wkly. 2015. doi:10.4414/smw.2015.14167.145:w14167. published online 31 July 2015.
   PubMed Web of Science ®Google Scholar
• Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline in 2013. J Antibiot. 2013;66(10):571–591.
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–690.
   PubMed Web of Science ®Google Scholar
• McCormick MH, McGuire JM, Pittenger GE, et al. Vancomycin, a new antibiotic. I Chemical Biologic Properties Antibiot Annu. 1955;3:606–611.
   PubMedGoogle Scholar
• Butler MS, Hansford KA, Blaskovich MA, et al. Glycopeptide antibiotics: back to the future. J Antibiot (Tokyo). 2014;67(9):631–644.
   PubMed Web of Science ®Google Scholar
• Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517(7535):455–459.
   PubMed Web of Science ®Google Scholar
• Forsyth C. Repairing the antibiotic pipeline-can the GAIN Act do it? Wash J Law Tech Arts. 2013;9(1):1–18.
   Google Scholar
• Outterson K. New Business Models for Sustainable Antibiotics. Working Groups on Antimicrobial Resistance. Paper 1. London: Chatham House, 2014. [cited 2015 Dec 19]. Available from: www.chathamhouse.org/sites/files/chathamhouse/public/Research/Global%20Health/0214SustainableAntibiotics.pdf
   Google Scholar
• Viale P, Giannella M, Tedeschi S, et al. Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians. Curr Opin Pharmacol. 2015;24:30–37.
   PubMed Web of Science ®Google Scholar